Top-Rated Stocks NASDAQ:GH Guardant Health - GH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $26.55 +0.60 (+2.31%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$25.80▼$26.9850-Day Range$25.01▼$33.7652-Week Range$24.20▼$77.72Volume3.50 million shsAverage Volume1.97 million shsMarket Capitalization$2.73 billionP/E RatioN/ADividend YieldN/APrice Target$57.64 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Guardant Health MarketRank™ ForecastAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside117.1% Upside$57.64 Price TargetShort InterestBearish7.15% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.78Based on 6 Articles This WeekInsider TradingAcquiring Shares$1.25 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($4.50) to ($3.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.80 out of 5 starsMedical Sector59th out of 988 stocksMedical Laboratories Industry3rd out of 24 stocks 4.4 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.64, Guardant Health has a forecasted upside of 117.1% from its current price of $26.55.Amount of Analyst CoverageGuardant Health has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.15% of the float of Guardant Health has been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guardant Health has recently increased by 13.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 66.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.95. Previous Next 3.8 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Guardant Health this week, compared to 2 articles on an average week.Search Interest60 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.MarketBeat Follows8 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,251,290.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions90.43% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($4.50) to ($3.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 45.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Guardant Health (NASDAQ:GH) StockGuardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.Read More Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GH Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comInsider Buying: Guardant Health, Inc. (NASDAQ:GH) CEO Purchases $224,890.00 in StockMarch 18, 2023 | americanbankingnews.comInsider Buying: Guardant Health, Inc. (NASDAQ:GH) CEO Purchases $1,026,400.00 in StockMarch 21, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 18, 2023 | americanbankingnews.comGuardant Health (NASDAQ:GH) Shares Gap Up on Insider Buying ActivityMarch 16, 2023 | msn.comGuardant Health Earnings Perspective: Return On Capital EmployedMarch 13, 2023 | finance.yahoo.comIn the wake of Guardant Health, Inc.'s (NASDAQ:GH) latest US$536m market cap drop, institutional owners may be forced to take severe actionsMarch 12, 2023 | americanbankingnews.comAnalysts Set Guardant Health, Inc. (NASDAQ:GH) Target Price at $59.57March 11, 2023 | americanbankingnews.comGuardant Health (NASDAQ:GH) Shares Gap Down to $28.88March 21, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 10, 2023 | msn.comCitigroup Downgrades Guardant Health (GH)March 10, 2023 | finance.yahoo.comGuardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood testMarch 9, 2023 | msn.comExact upgraded, Guardant downgraded as Citi revisits diagnostics coverageMarch 6, 2023 | finance.yahoo.com2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull MarketMarch 1, 2023 | msn.comLooking Into Guardant Health's Return On Capital EmployedFebruary 27, 2023 | msn.comAnalyst Expectations for Guardant Health's FutureFebruary 22, 2023 | benzinga.comEarnings Outlook For Guardant HealthFebruary 20, 2023 | finance.yahoo.comDoes Guardant Health (GH) Have Attractive Growth Prospects in the Long-Term?February 8, 2023 | wsj.comGuardant Health receives coverage from UnitedHealthcare for Guardant360(R) CDx blood test as companion diagnostic in advanced lung and breast cancerFebruary 6, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Guardant Health (GH)February 2, 2023 | markets.businessinsider.comGuardant Health Says Illumina Has No Basis For Challenging Ownership Of Its PatentsFebruary 2, 2023 | technews.tmcnet.comMagistrate Judge Issues Favorable Recommendation Regarding Guardant Health's Motion to Dismiss Lawsuit Brought by IlluminaFebruary 2, 2023 | finance.yahoo.comMagistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by IlluminaFebruary 1, 2023 | finance.yahoo.comGuardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023January 30, 2023 | finance.yahoo.comGuardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancerJanuary 29, 2023 | finance.yahoo.comGuardant Health (NASDAQ:GH) investors are sitting on a loss of 59% if they invested three years agoJanuary 20, 2023 | seekingalpha.comGuardant Health: Positive ECLIPSE Data Signals More UpsideJanuary 18, 2023 | reuters.comGH.OQ - | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GH Company Calendar Last Earnings11/04/2021Today3/21/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,793Year FoundedN/APrice Target and Rating Average Stock Price Forecast$57.64 High Stock Price Forecast$88.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+117.0%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($6.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-654,590,000.00 Net Margins-145.61% Pretax Margin-145.36% Return on Equity-242.65% Return on Assets-35.89% Debt Debt-to-Equity Ratio18.90 Current Ratio6.17 Quick Ratio5.90 Sales & Book Value Annual Sales$449.54 million Price / Sales6.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book45.02Miscellaneous Outstanding Shares102,660,000Free Float96,607,000Market Cap$2.73 billion OptionableNot Optionable Beta0.86 Key ExecutivesHelmy EltoukhyChairman & Co-Chief Executive OfficerAmirAli H. TalasazCo-Chief Executive Officer & DirectorAndrew AmentSenior Vice President-OperationsMichael BellChief Financial & Accounting OfficerDarya ChudovaSenior Vice President-TechnologyKey CompetitorsVeracyteNASDAQ:VCYTRadNetNASDAQ:RDNTFulgent GeneticsNASDAQ:FLGTViridian TherapeuticsNASDAQ:VRDNNateraNASDAQ:NTRAView All CompetitorsInsiders & InstitutionsHelmy EltoukhyBought 8,600 shares on 3/15/2023Total: $224,890.00 ($26.15/share)Amirali TalasazBought 40,000 shares on 3/13/2023Total: $1.03 M ($25.66/share)Rockefeller Capital Management L.P.Bought 6,626 shares on 3/6/2023Ownership: 0.038%OLD Mission Capital LLCBought 2,705 shares on 3/6/2023Ownership: 0.003%Voya Investment Management LLCBought 57,207 shares on 2/28/2023Ownership: 1.336%View All Insider TransactionsView All Institutional Transactions GH Stock - Frequently Asked Questions Should I buy or sell Guardant Health stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GH shares. View GH analyst ratings or view top-rated stocks. What is Guardant Health's stock price forecast for 2023? 13 equities research analysts have issued 12 month price targets for Guardant Health's shares. Their GH share price forecasts range from $33.00 to $88.00. On average, they predict the company's share price to reach $57.64 in the next year. This suggests a possible upside of 120.0% from the stock's current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts. How have GH shares performed in 2023? Guardant Health's stock was trading at $27.20 at the start of the year. Since then, GH shares have decreased by 3.7% and is now trading at $26.20. View the best growth stocks for 2023 here. Are investors shorting Guardant Health? Guardant Health saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 7,000,000 shares, an increase of 13.1% from the February 13th total of 6,190,000 shares. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is currently 3.4 days. Approximately 7.2% of the company's stock are sold short. View Guardant Health's Short Interest. When is Guardant Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our GH earnings forecast. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) issued its earnings results on Thursday, November, 4th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.16. The business had revenue of $94.80 million for the quarter, compared to the consensus estimate of $92.59 million. Guardant Health had a negative trailing twelve-month return on equity of 242.65% and a negative net margin of 145.61%. The firm's revenue was up 26.9% compared to the same quarter last year. During the same period last year, the company earned ($0.78) EPS. What ETFs hold Guardant Health's stock? ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Genomic Revolution ETF (ARKG), iShares U.S. Healthcare Providers ETF (IHF), Global X Founder-Run Companies ETF (BOSS), VanEck Biotech ETF (BBH), Goldman Sachs Future Consumer Equity ETF (GBUY) and Franklin Genomic Advancements ETF (HELX). What guidance has Guardant Health issued on next quarter's earnings? Guardant Health issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $525.00 million-$540.00 million, compared to the consensus revenue estimate of $554.00 million. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO). When did Guardant Health IPO? (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. What is Guardant Health's stock symbol? Guardant Health trades on the NASDAQ under the ticker symbol "GH." Who are Guardant Health's major shareholders? Guardant Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (2.53%), Alliancebernstein L.P. (2.46%), Price T Rowe Associates Inc. MD (1.66%), Geode Capital Management LLC (1.39%), Voya Investment Management LLC (1.34%) and Norges Bank (0.77%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Guardant Health's stock price today? One share of GH stock can currently be purchased for approximately $26.20. How much money does Guardant Health make? Guardant Health (NASDAQ:GH) has a market capitalization of $2.69 billion and generates $449.54 million in revenue each year. The company earns $-654,590,000.00 in net income (profit) each year or ($6.40) on an earnings per share basis. How many employees does Guardant Health have? The company employs 1,793 workers across the globe. How can I contact Guardant Health? Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258. This page (NASDAQ:GH) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.